drotaverin and Abdominal-Pain

To evaluate the efficacy and safety of Drotaverine hydrochroride in children with recurrent abdominal pain.. Double blind, randomized placebo-controlled trial.. Pediatric Gastroenterology clinic of a teaching hospital.. 132 children (age 4-12 y) with recurrent abdominal pain (Apley Criteria) randomized to receivedrotaverine (n=66) or placebo (n=66) orally.. Children between 4-6 years of age received 10 mL syrup orally (20 mg drotaverine hydrochloride or placebo) thrice daily for 4 weeks while children >6 years of age received one tablet orally (40 mg drotaverine hydrochloride or placebo) thrice daily for 4 weeks.. Primary: Number of episodes of pain during 4 weeks of use of drug/placebo and number of pain-free days. Secondary: Number of school days missed during the study period, parental satisfaction (on a Likert scale), and occurrence of solicited adverse effects.. Reduction in number of episodes of abdominal pain [mean (SD) number of episodes 10.3 (14) vs 21.6 (32.4); P=0.01] and lesser school absence [mean (SD) number of school days missed 0.25 (0.85) vs 0.71 (1.59); P=0.05] was noticed in children receiving drotaverine in comparison to those who received placebo. The number of pain-free days, were comparable in two groups [17.4 (8.2) vs 15.6 (8.7); P=0.23]. Significant improvement in parental satisfaction score was noticed on Likert scale by estimation of mood, activity, alertness, comfort and fluid intake. Frequency of adverse events during follow-up period was comparable between children receiving drotaverine or placebo (46.9% vs 46.7%; P=0.98).. Drotaverine hydrochloride is an effective and safe pharmaceutical agent in the management of recurrent abdominal pain in children.

Topics: Abdominal Pain; Absenteeism; Administration, Oral; Child; Child, Preschool; Chronic Pain; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; India; Male; Papaverine; Treatment Outcome

Topics: Abdominal Pain; Adult; Butylscopolammonium Bromide; Female; Humans; Hyperalgesia; Irritable Bowel Syndrome; Male; Pain Measurement; Pain Threshold; Papaverine; Parasympatholytics; Surveys and Questionnaires; Treatment Outcome; Viscera

Topics: Abdominal Pain; Chronic Pain; Female; Gastrointestinal Diseases; Humans; Male; Papaverine

Topics: Abdominal Pain; Chronic Pain; Female; Gastrointestinal Diseases; Humans; Male; Papaverine

The of antihelmintic preparation albendazole using in the complex treatment of patients with chronic pancreatitis with the concomitant ascaridosis was promote regression of clinical demonstration of basic and concomitant diseases (P < 0.05). Options of coprogram and the structural state of pancreas from data of ultrasonography in marks by Marseille-Cambridge classification of chronic pancreatitis, after the conducted treatment became the better (P < 0.05), that established expedience of the use of albendazole in complex treatment of patients with a chronic pancreatitis with a concomitant ascaridosis.

Topics: Abdominal Pain; Albendazole; Analgesics; Animals; Anthelmintics; Ascariasis; Ascaris; Drug Therapy, Combination; Dysbiosis; Dyspepsia; Feces; Female; Gastrointestinal Agents; Humans; Male; Pancreas; Pancreatitis, Chronic; Pancrelipase; Papaverine; Treatment Outcome